ライフサイエンスコーパス: nitrogen mustard

1 ed by antitumor agents such as cisplatin and nitrogen mustards.

2 by conventional cross-linking agents such as nitrogen mustards.

3 ounds in all series are prodrugs of bis-iodo nitrogen mustards.

4 rom o- and p-amino and p-methylamino aniline nitrogen mustards.

5 lesions in a pattern similar to conventional nitrogen mustards.

6 rtime discovery of the lymphotoxic action of nitrogen mustards.

7 with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intra

8 ontributions of NER and BER to the repair of nitrogen mustard adducts may not be the same genome wide

9 ortance of the two pathways in the repair of nitrogen mustard adducts.

10 se (GST) isoforms P1-1 and A1-1 to produce a nitrogen mustard alkylating agent.

11 BR384 is the nitrogen mustard analog of [4-[[N-(3-chlorophenyl)carbam

12 radiation and two DNA cross-linking agents, nitrogen mustard and cisplatinum.

13 covalent sequence specificity of a series of nitrogen mustard and imidazole-containing analogues of d

14 posure to three cytotoxic agents (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU))

15 The former moiety is a DNA damaging nitrogen mustard and the latter is a ligand for the ER.

16 ing treatment with bis-electrophiles such as nitrogen mustards and cisplatin is the N7 position of gu

17 nes and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin.

18 utic alkylating agents, such as bifunctional nitrogen mustards and cisplatins, generate interstrand D

19 Cisplatin and its derivatives, nitrogen mustards and mitomycin C, are used widely in ca

20 k formation, produced by the clinically used nitrogen mustard antitumour drug mechlorethamine (HN2),

21 tallimustine, which contains a benzoic acid nitrogen mustard appended to the minor groove DNA-bindin

22 owing the administration of "super" doses of nitrogen mustard, autologous bone marrow was infused int

23 sponding 3,5-difluorophenol and -aniline (4)-nitrogen mustards by the enzyme carboxypeptidase G2 (CPG

24 The nitrogen mustard Chlorambucil (Chl) generates covalent a

25 yribonucleotides (ODNs) bearing the reactive nitrogen mustard chlorambucil have been used as sequence

26 or, a triphenylphosphonium derivative of the nitrogen mustard chlorambucil.

27 to protect cells from the cytotoxicity of a nitrogen mustard, chlorambucil.

28 d kinetics for the monofunctional binding of nitrogen mustard class of anticancer drugs to purine bas

29 The use of macrocyclic nitrogen mustard complexes represents a promising new st

30 Nine new nitrogen mustard compounds derived from 2,6-difluoro-4-h

31 emonstrated in a shuttle vector system using nitrogen mustard-conjugated oligodeoxyribonucleotides (O

32 Nitrogen mustard cross-linking studies on a family of GA

33 Specifically, the nitrogen mustard cyclophosphamide induces an acute secre

34 In the case of nitrogen mustard DNA adduct processing, equal involvemen

35 Nitrogen mustard drugs are cytotoxic, but usually unsele

36 with that required for cross-linking by two nitrogen mustard drugs, mechlorethamine and melphalan.

37 mation of interstrand N+2 DNA cross-links by nitrogen mustards, e.g., melphalan and mechlorethamine.

38 Antitumor agents of the nitrogen mustard family and mitomycin C form interstrand

39 of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed

40 The bifunctional alkylating anticancer drug nitrogen mustard forms a variety of DNA lesions, includi

41 A plasmid with a single nitrogen mustard (HN2) interstrand cross-link (inter-HN2

42 itivity to methyl methanesulfonate (MMS) and nitrogen mustard (HN2).

43 to CDDP and another DNA crosslinking agent, nitrogen mustard (HN2).

44 e effects of a DNA alkylating agent known as nitrogen mustard (HN2).

45 inking agents, such as mitomycin C (MMC) and nitrogen mustard (HN2).

46 A2780(100) was 5 - 10-fold more resistant to nitrogen mustards (IC50 of 50 - 60 microM) and other DNA

47 e have synthesized a panel of model unhooked nitrogen mustard ICLs to systematically investigate how

48 d C studies, with a 75% to 83% lower dose of nitrogen mustard in addition to omission of procarbazine

49 and mag1 disruptants show elevated levels of nitrogen mustard-induced forward mutation.

50 re used to construct a plasmid with a single nitrogen mustard interstrand cross-link (inter-HN2-pTZSV

51 A polymerase II (polB) are hypersensitive to nitrogen mustard killing, E. coli appears to have two pa

52 me of processing of a substrate containing a nitrogen mustard-like ICL two nucleotides in the duplex

53 s were found to be involved in the repair of nitrogen mustard (mechlorethamine)- and cisplatin-induce

54 by conventional crosslinking agents such as nitrogen mustard, melphalan or cisplatin which bind in t

55 These agents include procarbazine, nitrogen mustard, melphalan, nitrosoureas (> or = 2 cycl

56 The nitrogen mustards, melphalan and chlorambucil, were both

57 ation frequencies, we found that cisplatin-, nitrogen mustard-, mitomycin-, and carmustine-induced DN

58 tion of interstrand 5'-GNC-3' cross-links by nitrogen mustards, modify the electrostatics of the majo

59 Measurements of repair rates of nitrogen mustard N-alkylpurine adducts in the highly tra

60 stogenic effects of several chemotherapeutic nitrogen mustards (namely, mechlorethamine, melphalan, a

61 DNA alkylating agents like nitrogen mustard (NM) are easily absorbed through the sk

62 Nitrogen mustards (NMs) are DNA-alkylating compounds tha

63 ent cell death in the presence of cisplatin, nitrogen mustard or thapsigargin.

64 A nitrogen mustard placed on the 5'-end of the purine moti

65 leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected again

66 with PR104A, an experimental DNA alkylating nitrogen mustard prodrug currently under investigation f

67 -104 is converted systemically to PR-104A, a nitrogen mustard prodrug designed to target tumor hypoxi

68 PR-104, a phosphate ester of the nitrogen mustard prodrug PR-104A, has shown evidence of

69 We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high l

70 ropionyl-( R)- (-) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activate

71 agents, such as methylators and crosslinking nitrogen mustards, represent a major risk factor for acu

72 ty and stability of the intermediate in both nitrogen mustards, respectively.

73 ent with the alkylating agents melphalan and nitrogen mustard resulted in 3.8- to 7.3-fold greater se

74 air pathways are epistatic to each other for nitrogen mustard sensitivity.

75 Nitrogen mustards such as mechlorethamine have previousl

76 We report a series of ROS-activated aromatic nitrogen mustards that selectively kill chronic lymphocy

77 In the case of cells treated with nitrogen mustard the higher levels coincided with cells

78 Therefore, selectively targeting nitrogen mustards to cancer cell mitochondria based on D

79 site-specific ICLs mimicking those formed by nitrogen mustards to facilitate the studies of cellular

80 e of the tirapazamine analogue 18a bearing a nitrogen mustard unit at the 6-position, it was found th

81 ard this end, tirapazamine analogues bearing nitrogen mustard units were prepared.

82 ridinoadenylates of the form 1 and a related nitrogen mustard variant have been constructed using a n

83 2% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) f

84 te, cytarabine, cyclophosphamide, etoposide, nitrogen mustard, vincristine, procarbazine, and prednis

85 ix, and the suppression was minimal when the nitrogen mustard was conjugated at only one end.

86 of diaryl and alkylaryl sulfoxide-containing nitrogen mustards were synthesized and evaluated for the

87 Nitrogen mustards, widely used as chemotherapeutics, hav